We've invested over 2 million dollars in preeclampsia research
February 2023 - The 2023 Vision Grant application phase is now open.
The Preeclampsia Foundation's affiliate organization Preeclampsia Foundation Canada will award two medical research Vision Grants to study preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy, up to $25,000 CAD.
Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Post-doctoral, Clinical Fellows, or Early Stage Investigators only are eligible to apply. Projects with potential to alter clinical management and improve patient outcomes will receive priority, but any well-considered research proposal will be accepted for review. International applications are welcome; however, submissions must be in English. The Foundation has committed to funding grants that address known research knowledge gaps.
The application deadline is Friday, April 14, 2023, with award notification in August 2023.
Questions? Contact VisionGrants@preeclampsia.org
PREVIOUS VISION GRANT RECIPIENTS
August 2022 - The 2023 Peter Joseph Pappas Research Grant application cycle is now closed.
Named for the infant son of preeclampsia survivor Lauren Pappas and her husband Clement, the program seeks to award multiple grants totaling up to $200,000 each year. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Letters of Intent that are of interest to the scientific review committee and the Preeclampsia Foundation’s Board of Directors will then be invited to submit full applications by October 8, 2022 with award decisions rendered in December 2022.
Read more about the Peter Joseph Pappas Research Grant Program.
Questions? Contact PJPGrants@preeclampsia.org
PREVIOUS PETER JOSEPH PAPPAS GRANT RECIPIENTS
Please note: The EMPOWER program is not currently being funded. No applications are being accepted at this time.
EMPOWER (EMpowering Progress in Obstetric and Women's hEalth Research) was established to create partnerships between mentors and single sites or groups within low- and middle-income countries to improve clinical and health services research into the hypertensive disorders of pregnancy.
When available, funding is for a two-year research project. The immediate objective is the completion of a project designed by a local investigator and, when appropriate, the dissemination of the results of the study to change practices and improve care.
EMPOWER is a collaboration of the International Society for the Study of Hypertension in Pregnancy, the Preeclampsia Foundation, PRE-EMPT/Global Pregnancy Collaboration, and supporting organization New Zealand Action on Pre-eclampsia.
PREVIOUS EMPOWER GRANT RECIPIENTS
Questions? Contact email@example.com
Please contact our Research Manager if you would like the Preeclampsia Foundation to help you recruit participants for a research study or focus group, or have any questions about the Preeclampsia Registry.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
The Preeclampsia Foundation's published research results.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...